Table 3. Enhancement of viral inactivation activity of the gp120-targeting proteins against primary HIV-1 virions in the absence (alone) or presence (in mixture) of the gp41-targeting fusion inhibitor T20, T2635 or SFT.
| Combined with | 2Dm2m | 4Dm2m | ||||
|---|---|---|---|---|---|---|
| EC50 (nM) | Enhancement (fold) | EC50 (nM) | Enhancement (fold) | |||
| Alone | In mixture | Alone | In mixture | |||
| US4(GS007) (B, R5) | ||||||
| T20 | 0.88 | 0.49 | 1.8 | 0.16 | 0.13 | 1.2 |
| T2635 | 0.88 | 0.17 | 5.2 | 0.16 | 0.08 | 2.0 |
| SFT | 0.88 | 0.27 | 3.3 | 0.16 | 0.10 | 1.6 |
| 92UG024 (D, X4) | ||||||
| T20 | 11.4 | 2.38 | 4.8 | 1.85 | 0.25 | 7.4 |
| T2635 | 11.4 | 0.18 | 63 | 1.85 | 0.18 | 10 |
| SFT | 11.4 | 0.24 | 47 | 1.85 | 0.27 | 6.9 |
| 92TH009 (A/E, R5) | ||||||
| T20 | 1.76 | 0.22 | 8.0 | 0.39 | 0.18 | 2.2 |
| T2635 | 1.76 | 0.27 | 6.5 | 0.39 | 0.12 | 3.3 |
| SFT | 1.76 | 0.28 | 6.3 | 0.39 | 0.17 | 2.3 |
| BCF02 (O, R5) | ||||||
| T20 | 3.79 | 1.69 | 2.2 | 1.77 | 1.12 | 1.6 |
| T2635 | 3.79 | 0.95 | 4.0 | 1.77 | 0.30 | 5.9 |
| SFT | 3.79 | 0.90 | 4.2 | 1.77 | 1.36 | 1.3 |
Data are representative of testing in triplicate (mean).